Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038987 · ClinicalTrials.gov registry record · Phase 1
Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 330
- Enrollment target
NCT00038987 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 330 participants.
The verdict
NCT00038987, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 330 participants
- Enrollment target
Study Summary
To define the safety of vaccination with APSV as determined by the reactogenicity of the vaccine and the development of expected and un-expected adverse events associated with vaccination. To assess the proportion of individuals who respond to vaccination with a "take" (those who form a visible lesion at the injection site) 6 to 8 days after the vaccination.
Interventions
- BIOLOGICAL Wetvax (APSV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2002-05 |
| Est. Completion | 2002-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038987
The ClinicalTrials.gov registry entry for NCT00038987 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Wetvax (APSV) is the first listed.
NCT00038987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038987 about?
NCT00038987 is a clinical study titled "Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT". To define the safety of vaccination with APSV as determined by the reactogenicity of the vaccine and the development of expected and un-expected adverse events associated with vaccination. To assess the proportion of individuals who respond to vaccination with a "take" (those who form a visible les...
What is the current status of trial NCT00038987?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 330 participants. The study started on 2002-05. Estimated completion is 2002-08.
What interventions are being tested in trial NCT00038987?
The interventions under investigation include: Wetvax (APSV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00038987?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.